MRK Merck & Company Inc
Company Analysis
Latest News
Merck Shares Slip After Expected 42% Melanoma Risk Reduction
Merck and partner Moderna presented detailed Phase 3 results for intismeran, a personalized cancer vaccine, combined with Keytruda for melanoma. The data were...
Merck CEO Downplays Cost Concerns for Personalized Cancer Vaccine Intismeran
Merck CEO Rob Davis states cost is not a barrier to access for its investigational personalized cancer vaccine, Intismeran. Davis expressed confidence Merck...
🔴 Merck is trading 3.3% down amid a wider U.S. market selloff
Merck is trading at $144.94 (-3.30%), with broad risk-off pressure a likely contributor, though no company-specific cause is confirmed. - On October 22, 2026,...
Merck Wins EU Approval for KEYTRUDA-Padcev in Resectable Bladder Cancer
Merck announced on October 21, 2026, that the European Commission (EC) approved KEYTRUDA in combination with Astellas and Pfizer’s Padcev for adults with...
🟢 Merck is trading 3.66% up today as healthcare stocks rallied
Merck is trading at $148.89, up 3.66%, in a move most consistent with healthcare-sector buying, though the exact intraday cause is unconfirmed. - No fresh,...
Merck Opens $500 Million AI-Powered Research Facility in Pennsylvania
Merck & Co. inaugurated its new Advance Bioanalytical Facility at its West Point, Pennsylvania, campus on October 15, 2026. The state-of-the-art building...
🟢 Merck is trading 3.01% up today after Phase 3 melanoma vaccine trial success
Merck is trading 3.01% up at $146.25 after Merck and Moderna’s personalized cancer vaccine, used with Keytruda, succeeded in a Phase 3 melanoma trial. - Merck...
Merck to Present Phase 3 Melanoma Data at ESMO, Following Trial Success
Merck will present first-time results from a pivotal Phase 3 trial at the European Society for Medical Oncology (ESMO) Congress in Madrid, October 23-27. The...
Merck’s Experimental Eye Drug Meets Trial Goal, but Raises Safety Concerns
Merck said its experimental drug remigromig met its primary goal in the Phase 2b/3 BRUNELLO study for diabetic macular edema (DME), a leading cause of vision...
Halozyme Wins Order Blocking Merck's Injectable Keytruda in Eight European Markets
A Dutch patent court ruled in favor of Halozyme Therapeutics, finding that Merck's subcutaneous (under-the-skin) version of its cancer drug Keytruda infringes...
🔴 Merck is trading 3.06% down today amid Vaxcyte’s positive Phase 3 VAX-31 results
Merck is trading 3.06% lower at $139.88 amid Vaxcyte’s positive Phase 3 results for VAX-31; coverage does not explicitly attribute Merck’s decline to the...
Scotiabank Raises Merck & Co. Price Target to $180
Scotiabank increased its price target for Merck & Co. (MRK) to $180.00 from $155.00. This suggests a potential upside of approximately 22.8%. The firm...
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion
Merck & Co. has signed an exclusive global licensing agreement with Chinese biotech firm SciBrunch Therapeutics for its experimental cancer drug, SPR2015. The...
Merck, Daiichi Sankyo Pull Lung Cancer Filing After FDA Data Setback
Merck and Daiichi Sankyo voluntarily withdrew their U.S. Biologics License Application (BLA) for ifinatamab deruxtecan, an experimental therapy. The...
Merck, Eisai Win FDA Approval for Welireg Combo, Outperforming Standard Care
The U.S. Food and Drug Administration (FDA) approved Merck’s Welireg (belzutifan) in combination with Eisai’s Lenvima (lenvatinib) for adults with advanced...
Merck Eye Drug Remigromig Matches Standard Treatment in Pivotal Study
Merck reported positive topline results from the pivotal Phase 2b/3 BRUNELLO study for remigromig. This investigational treatment targets diabetic macular...
Merck wins Japan approval for Keytruda injection, slashing treatment times
Japan’s Ministry of Health, Labour and Welfare approved Merck’s KEYTRUDA QLEX for subcutaneous injection across all existing indications. The formulation will...
Merck Price Target Raised Significantly by Leerink Partners
Leerink Partners reiterated an "Outperform" rating for Merck & Co. (MRK). The firm increased its 12-month price target for Merck to $161 from $127. This...
Inhibrx Therapy Nearly Doubles Keytruda Response in Head and Neck Cancer
Inhibrx Biosciences reported that its experimental drug, INBRX-106, combined with Merck’s Keytruda outperformed Keytruda alone in a Phase 2 trial. The...
Guggenheim Raises Merck Price Target to $170 on Cancer Drug Optimism
Guggenheim reiterated its "Buy" rating for Merck & Co. The firm raised its price target to $170 from $146. This decision follows increased sales estimates for...